Search research articles
Contact Us
Filters
Showing results (21-30 of 30) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 30 results.
The European Respiratory Journal
|
February 4, 2017
Urinary prostanoids in preschool wheeze
Jonathan Grigg, Abigail Whitehouse, Hitesh Pandya, et al.
ERJ Open Research
|
February 25, 2026
FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthma
Jonathan Corren, Fred Reid, Rachel Moate, et al.
The Lancet. Respiratory Medicine
|
February 15, 2026
Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials
Alberto Papi, Robert A Wise, David J Jackson, et al.
Eclinicalmedicine
|
August 20, 2025
Safety of budesonide/glycopyrronium/formoterol fumarate dihydrate delivered by HFO-1234ze versus HFA-134a in chronic obstructive pulmonary disease: a phase 3, multi-site, randomised, double-blind, parallel-group, active-comparator study
Omar S Usmani, Fernando J Martinez, Hitesh Pandya, et al.
The European Respiratory Journal
|
March 28, 2025
A phase 2a trial of the IL-33 mAb tozorakimab in patients with COPD: FRONTIER-4
Dave Singh, Patricia Guller, Fred Reid, et al.
Respiratory Research
|
April 14, 2026
Elarekibep, an inhaled anti-IL-4 receptor alpha Anticalin, in moderate-to-severe asthma: a randomized, placebo-controlled phase 2a study (APATURA)
Tania Hugo, Andrew R Harper, Jacob Leander, et al.
Clinical Pharmacology and Therapeutics
|
December 20, 2023
A Randomized Phase I Study of the Anti-Interleukin-33 Antibody Tozorakimab in Healthy Adults and Patients With Chronic Obstructive Pulmonary Disease
Fred Reid, Dave Singh, Muna Albayaty, et al.
The New England Journal of Medicine
|
May 19, 2025
As-Needed Albuterol-Budesonide in Mild Asthma
Craig LaForce, Frank Albers, Anna Danilewicz, et al.
ERJ Open Research
|
October 23, 2023
A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2
Tom Wilkinson, Anthony De Soyza, Miles Carroll, et al.
BMJ Open
|
March 11, 2019
Assessment of breath volatile organic compounds in acute cardiorespiratory breathlessness: a protocol describing a prospective real-world observational study
Wadah Ibrahim, Michael Wilde, Rebecca Cordell, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 30) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 30 results.
The European Respiratory Journal
|
February 4, 2017
Urinary prostanoids in preschool wheeze
Jonathan Grigg, Abigail Whitehouse, Hitesh Pandya, et al.
ERJ Open Research
|
February 25, 2026
FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthma
Jonathan Corren, Fred Reid, Rachel Moate, et al.
The Lancet. Respiratory Medicine
|
February 15, 2026
Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials
Alberto Papi, Robert A Wise, David J Jackson, et al.
Eclinicalmedicine
|
August 20, 2025
Safety of budesonide/glycopyrronium/formoterol fumarate dihydrate delivered by HFO-1234ze versus HFA-134a in chronic obstructive pulmonary disease: a phase 3, multi-site, randomised, double-blind, parallel-group, active-comparator study
Omar S Usmani, Fernando J Martinez, Hitesh Pandya, et al.
The European Respiratory Journal
|
March 28, 2025
A phase 2a trial of the IL-33 mAb tozorakimab in patients with COPD: FRONTIER-4
Dave Singh, Patricia Guller, Fred Reid, et al.
Respiratory Research
|
April 14, 2026
Elarekibep, an inhaled anti-IL-4 receptor alpha Anticalin, in moderate-to-severe asthma: a randomized, placebo-controlled phase 2a study (APATURA)
Tania Hugo, Andrew R Harper, Jacob Leander, et al.
Clinical Pharmacology and Therapeutics
|
December 20, 2023
A Randomized Phase I Study of the Anti-Interleukin-33 Antibody Tozorakimab in Healthy Adults and Patients With Chronic Obstructive Pulmonary Disease
Fred Reid, Dave Singh, Muna Albayaty, et al.
The New England Journal of Medicine
|
May 19, 2025
As-Needed Albuterol-Budesonide in Mild Asthma
Craig LaForce, Frank Albers, Anna Danilewicz, et al.
ERJ Open Research
|
October 23, 2023
A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2
Tom Wilkinson, Anthony De Soyza, Miles Carroll, et al.
BMJ Open
|
March 11, 2019
Assessment of breath volatile organic compounds in acute cardiorespiratory breathlessness: a protocol describing a prospective real-world observational study
Wadah Ibrahim, Michael Wilde, Rebecca Cordell, et al.
Page
of 3